• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Molecular Partners AG

    7/17/25 4:06:33 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MOLN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    MOLECULAR PARTNERS AG

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)


    60853G106

    (CUSIP Number)


    09/30/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    60853G106


    1Names of Reporting Persons

    UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SWITZERLAND
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,086,452.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,144,607.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,144,607.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:  This filing is being submitted as of September 30, 2024. As of this reporting date, the combined positions of UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, an aggregation unit within the Asset Management business division of UBS Group AG, were above the reportable threshold. The delay resulted from an inadvertent data issue related to UBS / Credit Suisse systems integration, which has now been identified and resolved.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MOLECULAR PARTNERS AG
    (b)Address of issuer's principal executive offices:

    WAGISTRASSE 14, Z?RICH-SCHLIEREN, SWITZERLAND, 8952
    Item 2. 
    (a)Name of person filing:

    UBS Group AG
    (b)Address or principal business office or, if none, residence:

    UBS Group AG Bahnhofstrasse 45 PO Box CH-8021 Zurich, Switzerland
    (c)Citizenship:

    Switzerland
    (d)Title of class of securities:

    Common Shares
    (e)CUSIP No.:

    60853G106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,144,607.00
    (b)Percent of class:

    5.84  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2,086,452.00

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2,144,607.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Ownership of More than 5 Percent on Behalf of Another Person. Accounts managed on a discretionary basis by the UBS Asset Management division of UBS Group AG (UBS AM) have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities. To the best of our knowledge, no account holds more than 5 percent of the outstanding securities being reported in this filing.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Identification: UBS Asset Management (Americas) LLC. Classification: IA In addition to UBS Group AG, the following UBS Asset Management affiliates and subsidiaries are part of the UBS Asset Management division included in this filing: UBS Asset Management (Europe) S.A., UBS Asset Management Switzerland AG, and UBS Fund Management (Switzerland) AG
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    UBS AM is composed of wholly-owned subsidiaries and branches of UBS Group AG. UBS Group AG is reporting direct and indirect beneficial ownership of holdings. None of the reporting persons affirm the existence of a group within the meaning of Rule 13d 5(b)(1).
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
     
    Signature:/s/ Andrew Johnson
    Name/Title:Director
    Date:07/17/2025
    Get the next $MOLN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MOLN

    DatePrice TargetRatingAnalyst
    8/30/2022Outperform → Sector Perform
    RBC Capital Mkts
    8/29/2022$30.00 → $8.00Outperform → Mkt Perform
    SVB Leerink
    5/25/2022Underperform → Neutral
    Credit Suisse
    4/27/2022Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $MOLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

    MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first radio-DARPin program MP0712 and initiation of Phase 1 trial expected by end 2025; update on early imaging work planned in Q4 2025; expanded strategic radiotherapy partnership with Orano MedAppointed Martin Steegmaier, Ph.D. as CSO and member of Executive CommitteeCash and cash equivalents and short-term time deposits total of CHF 114 million as of June 30, 2025, extending runway into 2028. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GL

    8/25/25 4:00:00 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

    Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company's Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug dev

    8/21/25 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

    MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor accumulation and attractive biodistribution shown in vivo, selective binding to membrane-bound MSLN with positive tumor to kidney ratio ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company") and Orano Med, a clini

    6/22/25 4:00:00 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MOLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Molecular Partners AG downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Molecular Partners AG from Outperform to Sector Perform

    8/30/22 7:28:18 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners AG downgraded by SVB Leerink with a new price target

    SVB Leerink downgraded Molecular Partners AG from Outperform to Mkt Perform and set a new price target of $8.00 from $30.00 previously

    8/29/22 7:20:11 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners AG upgraded by Credit Suisse

    Credit Suisse upgraded Molecular Partners AG from Underperform to Neutral

    5/25/22 7:20:11 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MOLN
    SEC Filings

    View All

    SEC Form 6-K filed by Molecular Partners AG

    6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)

    8/25/25 4:01:43 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Molecular Partners AG

    SCHEDULE 13G - MOLECULAR PARTNERS AG (0001745114) (Subject)

    7/17/25 4:06:33 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Molecular Partners AG

    S-8 - MOLECULAR PARTNERS AG (0001745114) (Filer)

    6/25/25 4:01:06 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MOLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Molecular Partners AG

    SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)

    10/29/24 4:32:33 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Molecular Partners AG

    SC 13D - MOLECULAR PARTNERS AG (0001745114) (Subject)

    11/20/23 5:07:45 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Molecular Partners AG (Amendment)

    SC 13G/A - MOLECULAR PARTNERS AG (0001745114) (Subject)

    11/7/23 4:41:38 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MOLN
    Leadership Updates

    Live Leadership Updates

    View All

    Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

    Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company's Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug dev

    8/21/25 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MOLN
    Financials

    Live finance-specific insights

    View All

    Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

    MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first radio-DARPin program MP0712 and initiation of Phase 1 trial expected by end 2025; update on early imaging work planned in Q4 2025; expanded strategic radiotherapy partnership with Orano MedAppointed Martin Steegmaier, Ph.D. as CSO and member of Executive CommitteeCash and cash equivalents and short-term time deposits total of CHF 114 million as of June 30, 2025, extending runway into 2028. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GL

    8/25/25 4:00:00 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners Reports Financial Results and Highlights from Q1 2025

    Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programsData from dosing cohort 8 in Phase 1/2a trial of MP0533 demonstrate increased rates and depth of responses; study protocol amendment now approved, and dosing cohort 9 enrollment initiated, additional data expected in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53

    5/15/25 4:00:00 PM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

    Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also host a conference call on March 7 on its full-year 2024 financial report. The Annual Report is due to be published March 6. Details of the events:

    2/28/25 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care